Looking for winners in geographic atrophy
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
Astra puts a bet on gene editing
Logicbio gives Astra a novel gene-editing technology at a bargain price.
PCSK9 pipeline shows signs of saturation
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
Can Kalvista make HAE after Pharvaris’s misstep?
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
ESC 2022 preview – who’s got the XI factor?
Bristol Myers Squibb/Johnson & Johnson and Bayer will soon get more hints about whether their Eliquis and Xarelto follow-ons can cut it.
